Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 4.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,043 shares of the company’s stock after selling 1,559 shares during the quarter. Yousif Capital Management LLC’s holdings in Neurocrine Biosciences were worth $5,056,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of NBIX. Brooklyn Investment Group lifted its stake in shares of Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after acquiring an additional 115 shares during the period. Blue Trust Inc. lifted its position in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares during the period. R Squared Ltd bought a new position in Neurocrine Biosciences during the 4th quarter valued at $61,000. UMB Bank n.a. increased its position in shares of Neurocrine Biosciences by 211.6% during the 4th quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after purchasing an additional 309 shares during the period. Finally, Truvestments Capital LLC bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter worth $63,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

NBIX has been the subject of several research reports. Raymond James reaffirmed an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Morgan Stanley raised their price objective on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a research report on Tuesday. UBS Group boosted their target price on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. Piper Sandler restated an “overweight” rating and set a $160.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $148.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $166.85.

Insider Activity at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ingrid Delaet sold 1,091 shares of the company’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the completion of the sale, the insider now owns 2,507 shares of the company’s stock, valued at $338,445. This represents a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 222,693 shares of company stock valued at $32,718,279. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Down 0.5 %

NBIX stock opened at $150.51 on Friday. The company has a 50 day moving average of $138.41 and a two-hundred day moving average of $131.64. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The company has a market cap of $15.24 billion, a price-to-earnings ratio of 40.35 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 17.21% and a return on equity of 15.68%. On average, research analysts anticipate that Neurocrine Biosciences, Inc. will post 3.92 EPS for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.